GOVX vs. BIOR, MEIP, HCWB, AWH, FBRX, TXMD, KALA, JAN, CARA, and LGVN
Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Biora Therapeutics (BIOR), MEI Pharma (MEIP), HCW Biologics (HCWB), Aspira Women's Health (AWH), Forte Biosciences (FBRX), TherapeuticsMD (TXMD), KALA BIO (KALA), JanOne (JAN), Cara Therapeutics (CARA), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry.
GeoVax Labs (NASDAQ:GOVX) and Biora Therapeutics (NASDAQ:BIOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, valuation and community ranking.
Biora Therapeutics' return on equity of 0.00% beat GeoVax Labs' return on equity.
GeoVax Labs has higher revenue and earnings than Biora Therapeutics.
GeoVax Labs has a beta of 3.08, meaning that its share price is 208% more volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.
GeoVax Labs presently has a consensus target price of $14.00, suggesting a potential upside of 434.35%. Biora Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 2,146.52%. Given Biora Therapeutics' higher possible upside, analysts clearly believe Biora Therapeutics is more favorable than GeoVax Labs.
6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are held by institutional investors. 5.7% of GeoVax Labs shares are held by insiders. Comparatively, 51.0% of Biora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, GeoVax Labs had 3 more articles in the media than Biora Therapeutics. MarketBeat recorded 8 mentions for GeoVax Labs and 5 mentions for Biora Therapeutics. GeoVax Labs' average media sentiment score of 0.78 beat Biora Therapeutics' score of 0.50 indicating that GeoVax Labs is being referred to more favorably in the media.
GeoVax Labs received 10 more outperform votes than Biora Therapeutics when rated by MarketBeat users. Likewise, 94.12% of users gave GeoVax Labs an outperform vote while only 75.00% of users gave Biora Therapeutics an outperform vote.
Summary
GeoVax Labs beats Biora Therapeutics on 10 of the 15 factors compared between the two stocks.
Get GeoVax Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GeoVax Labs Competitors List
Related Companies and Tools
